Brilliant. I give useful classic actuarial guidance of revenues, to investors complaining about lack of revenue guidance, and you once again tell yet another poster how to suck eggs. No one compared MSB to an AI company. I just highlighted your lack of consistency in argument.
Putting your ego aside, using mortality rates we are all aware of, and the information provided, $90 million of initial Ryconcil revenue potential at just 10% reimbursement coverage in the US, the far more important takeaway, from simple analysis that even the most mathematically illiterate of investors should be able to compute.
MSB Price at posting:
$2.08 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)